PeptiDream, the Tokyo-based biopharmaceutical company have entered into a lucrative research collabortation with BIND Theraputics, the leader in the nanomedicine space. The research is focused on using state of the art peptide based theraputics in an aim to investigate the use of PeptiDreamâs macrocyclic peptides. The research will look into the macrocylic peptides as a targeting ligand component for Accurins aimed at modulating anti-tumour immunity.
PeptiDream aim to become industry leaders in the development of highly functional peptide theraputics, this collaboration with US-based BIND Theraputics could be set to help PeptiDream reach their goal. This new announcement goes on to further establish the string of recent collaborations that PeptiDream have organised in the last 5 years. The company have several ongoing funded discovery collaborations with a range of leading pharmaceutical companies including industry giants GlaxoSmithKiline, Myers-Squibb, Ipsen and Teijin. The Tokyo-based biopharmaceutical company have tactfully and strategically encouraged use of their PDPS (peptide-drug-conjugate) technology by making it available for use across a number of research projects.
Kiichi Kubota, President & CEO of PeptiDream, has pushed this continuous streak of research collaborations in his statement on the recent deal between BIND and PeptiDream expressed that ‘BIND is the leader in the nanomedicine space and we believe there are excellent synergies between the two companies that could lead to the discovery and development of some truly novel therapeutics.’
The research collaboration between PeptiDream and BIND Theraputics with see the PDPS technology owned by PeptiDream identify key macrocyclic peptides that are used as biologically active targeted ligands. BIND have done extensive research into certain targeting ligands to accelerate the focus on products that evoke tumour cell death and influence the tumour microenvironment to maximise the clinical benefit for patients.
Accurins are polymeric nanoparticles that contain and control the release of therapeutic payloads with diverse physical and chemical properties. The surface of Accurins can be functionalised with ligands to elicit a biological response seeking to enhance disease tissue accumulation. The new deal sets to meet previously unmet medical needs and set new standards in the industry field anti-tumour immunity research.